Ask AI
ProCE Banner Activity

Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

Podcast Episodes

Listen to Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, as they discuss multidisciplinary care of patients with HER2-negative/ultralow/low metastatic breast cancer, with a focus on ADCs.

Released: March 27, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC In partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is intended for community oncology teams caring for patients with metastatic breast cancer, including medical oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recommend ADC therapies to appropriate patients with HER2-negative/ultralow/low MBC based on the latest evidence, approvals, and expert recommendations​

  • Apply evidence-based guidelines to identify, manage, and counsel patients on AEs related to ADC therapy​

  • Integrate patients’ treatment goals, preferences, and quality of life considerations into decisions related to ADC therapy selection and supportive care

Disclosure

Primary Author

Aditya Bardia, MD, MPH, FASCO: consultant/advisor/speaker: Alyssum, AstraZeneca/Daiichi Sankyo, Genentech, Gilead, Lilly, Menarini, Merck, Novartis, Pfizer; researcher: AstraZeneca/Daiichi Sankyo, Genentech, Gilead, Lilly, Menarini, Merck, Novartis, Onkure, Pfizer.

Ruta Rao, MD: consultant/advisor/speaker: AstraZeneca, DSI, Genentech, Lilly.